Novel Pharmacotherapeutic Interventions for Cannabis Use Disorder

Current Addiction Reports

Volumn 3, Issue 2, 2016, Pages 214-220

  Mason, Brittany L ^a   Mustafa, Alaa ^a   Filbey, Francesca ^b   Brown, E Sherwood ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Cannabis; Pharmacological; Substance abuse; Treatment; Use disorder

Indexed keywords

EID: 85050746700     PISSN: None     EISSN: 21962952     Source Type: Journal    
DOI: 10.1007/s40429-016-0094-y     Document Type: Review

References (51)

1. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. JAMA. 2004;291(17):2114–21. doi:10.1001/jama.291.17.2114.
2. Copeland J, Swift W, Roffman R, Stephens R. A randomized controlled trial of brief cognitive-behavioral interventions for cannabis use disorder. J Subst Abuse Treat. 2001;21(2):55–64. discussion 5–6.
3. Moore BA, Budney AJ. Relapse in outpatient treatment for marijuana dependence. J Subst Abuse Treat. 2003;25(2):85–9.
4. Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. J Consult Clin Psychol. 2000;68(5):898–908.
5. Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol. 1994;62(1):92–9.
6. Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend. 2010;112(1–2):39–45. doi:10.1016/j.drugalcdep.2010.05.010.
7. Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, et al. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction. 2013;108(6):1084–94. doi:10.1111/add.12108.
8. Weinstein AM, Miller H, Bluvstein I, Rapoport E, Schreiber S, Bar-Hamburger R, et al. Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. Am J Drug Alcohol Abuse. 2014;40(1):16–22. doi:10.3109/00952990.2013.819362.
9. Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict. 2009;18(1):53–64. doi:10.1080/10550490802408936.
10. Penetar DM, Looby AR, Ryan ET, Maywalt MA, Lukas SE. Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study. Subst Abuse. 2012;6:63–71. doi:10.4137/sart.s9706.
11. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Cooper ZD, et al. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl). 2010;211(2):233–44. doi:10.1007/s00213-010-1888-6.
12. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, et al. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend. 2009;105(1–2):132–8. doi:10.1016/j.drugalcdep.2009.06.022.
13. Kedzior KK, Laeber LT. A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population--a meta-analysis of 31 studies. BMC Psychiatry. 2014;14:136. doi:10.1186/1471-244x-14-136.
14. Sami MB, Rabiner EA, Bhattacharyya S. Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. Eur Neuropsychopharmacol. 2015. doi:10.1016/j.euroneuro.2015.03.011.
15. McRae-Clark AL, Carter RE, Price KL, Baker NL, Thomas S, Saladin ME, et al. Stress- and cue-elicited craving and reactivity in marijuana-dependent individuals. Psychopharmacology (Berl). 2011;218(1):49–58. doi:10.1007/s00213-011-2376-3.
16. McRae-Clark AL, Baker NL, Maria MM, Brady KT. Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacology (Berl). 2013;228(4):623–31. doi:10.1007/s00213-013-3062-4.
17. Sugarman DE, Poling J, Sofuoglu M. The safety of modafinil in combination with oral 9-tetrahydrocannabinol in humans. Pharmacol Biochem Behav. 2011;98(1):94–100. doi:10.1016/j.pbb.2010.12.013.
18. McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, White KG, Brady KT. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. Am J Addict. 2010;19(6):481–9. doi:10.1111/j.1521-0391.2010.00076.x.
19. Schnell T, Koethe D, Krasnianski A, Gairing S, Schnell K, Daumann J, et al. Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study. Am J Addict. 2014;23(3):308–12. doi:10.1111/j.1521-0391.2014.12126.x.
20. Mariani JJ, Pavlicova M, Mamczur AK, Bisaga A, Nunes EV, Levin FR. Open-label pilot study of quetiapine treatment for cannabis dependence. Am J Drug Alcohol Abuse. 2014;40(4):280–4. doi:10.3109/00952990.2014.884102.
21. Geoffroy PA, Rolland B, Guardia D, Warembourg F, Cottencin O. Use of aripiprazole in treatment of cannabis dependence in a patient presenting with Borderline Personality Disorder. J Neuropsychiatry Clin Neurosci. 2012;24(2):E37. doi:10.1176/appi.neuropsych.11040088.
22. Anton RF, Kranzler H, Breder C, Marcus RN, Carson WH, Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol. 2008;28(1):5–12. doi:10.1097/jcp.0b013e3181602fd4.
23. Brown ES, Jeffress J, Liggin JD, Garza M, Beard L. Switching outpatients with bipolar or schizoaffective disorders and substance abuse from their current antipsychotic to aripiprazole. J Clin Psychiatry. 2005;66(6):756–60.
24. Levin FR, McDowell D, Evans SM, Nunes E, Akerele E, Donovan S, et al. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict. 2004;13(1):21–32.
25. Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012;37(7):1689–98. doi:10.1038/npp.2012.14. This recent trial demonstrated somewhat positive findings for CUD with gabapentin.
26. Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(1):70–7. doi:10.1001/jamainternmed.2013.11950.
27. Allsop DJ, Copeland J, Lintzeris N, Dunlop AJ, Montebello M, Sadler C, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry. 2014;71(3):281–91. doi:10.1001/jamapsychiatry.2013.3947.
28. Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W, Nunes EV. Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial. Drug Alcohol Depend. 2011;116(1–3):142–50. doi:10.1016/j.drugalcdep.2010.12.010.
29. Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, et al. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169(8):805–12. doi:10.1176/appi.ajp.2012.12010055. This study in adolescents suggested positive effects on cannabis use with N-acetylcysteine.
30. Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers. Neuropsychopharmacology. 2015. doi:10.1038/npp.2015.108.
31. Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, et al. Naltrexone does not attenuate the effects of intravenous Delta9-tetrahydrocannabinol in healthy humans. Int J Neuropsychopharmacol. 2012;15(9):1251–64. doi:10.1017/s1461145711001830.
32. Sofuoglu M, Sugarman DE, Carroll KM. Cognitive function as an emerging treatment target for marijuana addiction. Exp Clin Psychopharmacol. 2010;18(2):109–19. doi:10.1037/a0019295.
33. Briand LA, Gritton H, Howe WM, Young DA, Sarter M. Modulators in concert for cognition: modulator interactions in the prefrontal cortex. Prog Neurobiol. 2007;83(2):69–91. doi:10.1016/j.pneurobio.2007.06.007.
34. Degroot A, Kofalvi A, Wade MR, Davis RJ, Rodrigues RJ, Rebola N, et al. CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol Pharmacol. 2006;70(4):1236–45. doi:10.1124/mol.106.024661.
35. Mishima K, Egashira N, Matsumoto Y, Iwasaki K, Fujiwara M. Involvement of reduced acetylcholine release in Delta9-tetrahydrocannabinol-induced impairment of spatial memory in the 8-arm radial maze. Life Sci. 2002;72(4–5):397–407.
36. Justinova Z, Mascia P, Wu HQ, Secci ME, Redhi GH, Panlilio LV, et al. Reducing cannabinoid abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid. Nat Neurosci. 2013;16(11):1652–61. doi:10.1038/nn.3540.
37. Galvin JE, Cornblatt B, Newhouse P, Ancoli-Israel S, Wesnes K, Williamson D, et al. Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Alzheimer Dis Assoc Disord. 2008;22(1):30–8. doi:10.1097/WAD.0b013e3181630b81.
38. Lucas-Meunier E, Fossier P, Baux G, Amar M. Cholinergic modulation of the cortical neuronal network. Pflugers Arch. 2003;446(1):17–29. doi:10.1007/s00424-002-0999-2.
39. Deardorff WJ, Feen E, Grossberg GT. The use of cholinesterase inhibitors across all stages of Alzheimer’s disease. Drugs Aging. 2015. doi:10.1007/s40266-015-0273-x.
40. Theunissen EL, Heckman P, de Sousa Fernandes Perna EB, Kuypers KP, Sambeth A, Blokland A, et al. Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. Psychopharmacology (Berl). 2015;232(2):343–53. doi:10.1007/s00213-014-3667-2.
41. Martinet M, Fonlupt P, Pacheco H. Effects of cytidine-5′ diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. Arch Int Pharmacodyn Ther. 1979;239(1):52–61.
42. Petkov VD, Stancheva SL, Tocuschieva L, Petkov VV. Changes in brain biogenic monoamines induced by the nootropic drugs adafenoxate and meclofenoxate and by citicholine (experiments on rats). Gen Pharmacol. 1990;21(1):71–5.
43. Ulus IH, Wurtman RJ, Mauron C, Blusztajn JK. Choline increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum. Brain Res. 1989;484(1–2):217–27.
44. Licata SC, Penetar DM, Ravichandran C, Rodolico J, Palmer C, Berko J, et al. Effects of daily treatment with citicoline: a double-blind, placebo-controlled study in cocaine-dependent volunteers. J Addict Med. 2011;5(1):57–64. doi:10.1097/ADM.0b013e3181d80c93.
45. Coppola M, Mondola R. Palmitoylethanolamide: from endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence. Med Hypotheses. 2013;81(4):619–22. doi:10.1016/j.mehy.2013.07.016.
46. Coppola M, Mondola R. Potential use of Magnolia officinalis bark polyphenols in the treatment of cannabis dependence. Med Hypotheses. 2014;83(6):673–6. doi:10.1016/j.mehy.2014.09.015.
47. Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature. 2005;437(7058):556–9. doi:10.1038/nature04071.
48. Flores A, Maldonado R, Berrendero F. The hypocretin/orexin receptor-1 as a novel target to modulate cannabinoid reward. Biol Psychiatry. 2014;75(6):499–507. doi:10.1016/j.biopsych.2013.06.012.
49. Degoulet M, Stelly CE, Ahn KC, Morikawa H. L-type Ca channel blockade with antihypertensive medication disrupts VTA synaptic plasticity and drug-associated contextual memory. Mol Psychiatry. 2015. doi:10.1038/mp.2015.84.
50. Gomes I, Fujita W, Chandrakala MV, Devi LA. Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. Prog Mol Biol Transl Sci. 2013;117:207–65. doi:10.1016/b978-0-12-386931-9.00009-x.
51. Vallee M, Vitiello S, Bellocchio L, Hebert-Chatelain E, Monlezun S, Martin-Garcia E, et al. Pregnenolone can protect the brain from cannabis intoxication. Science. 2014;343(6166):94–8. doi:10.1126/science.1243985. This recent paper reported that pregnenolone blocked the brain effects of cannabis in an animal model.